145 results on '"Paterno, Giovangiacinto"'
Search Results
2. Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia
- Author
-
Travaglini, Serena, Silvestrini, Giorgia, Attardi, Enrico, Fanciulli, Maurizio, Scalera, Stefano, Antonelli, Silvia, Maurillo, Luca, Palmieri, Raffaele, Divona, Mariadomenica, Ciuffreda, Ludovica, Savi, Arianna, Paterno, Giovangiacinto, Ottone, Tiziana, Barbieri, Caterina, Maciejewski, Jaroslaw P., Gurnari, Carmelo, Ciliberto, Gennaro, and Voso, Maria Teresa
- Published
- 2024
- Full Text
- View/download PDF
3. The effect of COVID-19 on the frequency of Pneumocystis jirovecii pneumonia: a monocentric, retrospective, and observational study
- Author
-
Del Prete, Valentina, Paterno, Giovangiacinto, Cennamo, Oreste, Berrilli, Federica, and Di Cave, David
- Published
- 2023
- Full Text
- View/download PDF
4. The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia
- Author
-
Paterno, Giovangiacinto, Palmieri, Raffaele, Tesei, Cristiano, Nunzi, Andrea, Ranucci, Giorgia, Mallegni, Flavia, Moretti, Federico, Meddi, Elisa, Tiravanti, Ilaria, Marinoni, Massimiliano, Page, Camilla, Fagiolo, Solaria, Buzzatti, Elisa, Secchi, Roberto, Gurnari, Carmelo, Maurillo, Luca, Buccisano, Francesco, Venditti, Adriano, and Del Principe, Maria Ilaria
- Published
- 2024
- Full Text
- View/download PDF
5. Real-life experience of secondary prophylaxis with DOACs in splanchnic venous thrombosis during COVID-19 pandemic
- Author
-
Guarnera, Luca, Buzzatti, Elisa, Bonanni, Fabrizio, Paterno, Giovangiacinto, Riccitelli, Antonella, Forte, Vittorio, Venditti, Adriano, and Del Principe, Maria Ilaria
- Published
- 2023
- Full Text
- View/download PDF
6. ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
- Author
-
Buccisano, Francesco, Palmieri, Raffaele, Piciocchi, Alfonso, Arena, Valentina, Candoni, Anna, Melillo, Lorella, Calafiore, Valeria, Cairoli, Roberto, de Fabritiis, Paolo, Storti, Gabriella, Salutari, Prassede, Lanza, Francesco, Martinelli, Giovanni, Luppi, Mario, Capria, Saveria, Maurillo, Luca, Del Principe, Maria Ilaria, Paterno, Giovangiacinto, Irno Consalvo, Maria Antonietta, Ottone, Tiziana, Lavorgna, Serena, Voso, Maria Teresa, Fazi, Paola, Vignetti, Marco, Arcese, William, and Venditti, Adriano
- Published
- 2022
- Full Text
- View/download PDF
7. Terminal deoxynucleotidyl transferase (TdT) expression is associated with FLT3-ITD mutations in Acute Myeloid Leukemia
- Author
-
De Bellis, Eleonora, Ottone, Tiziana, Mercante, Lisa, Falconi, Giulia, Cugini, Elisa, Consalvo, Maria Irno, Travaglini, Serena, Paterno, Giovangiacinto, Piciocchi, Alfonso, Rossi, Elisa Linnea Lindfors, Gurnari, Carmelo, Maurillo, Luca, Buccisano, Francesco, Arcese, William, and Voso, Maria Teresa
- Published
- 2020
- Full Text
- View/download PDF
8. The effect of COVID-19 on the frequency of Pneumocystis jirovecii pneumonia: a monocentric, retrospective, and observational study
- Author
-
Prete, Valentina Del, primary, Paterno, Giovangiacinto, additional, Cennamo, Oreste, additional, Berrilli, Federica, additional, and Cave, David Di, additional
- Published
- 2023
- Full Text
- View/download PDF
9. Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells
- Author
-
Travaglini, Serena, Angelini, Daniela Francesca, Alfonso, Valentina, Guerrera, Gisella, Lavorgna, Serena, Divona, Mariadomenica, Nardozza, Anna Maria, Consalvo, Maria Irno, Fabiani, Emiliano, De Bardi, Marco, Neri, Benedetta, Forghieri, Fabio, Marchesi, Francesco, Paterno, Giovangiacinto, Cerretti, Raffaella, Barragan, Eva, Fiori, Valentina, Dominici, Sabrina, Del Principe, Maria Ilaria, Venditti, Adriano, Battistini, Luca, Arcese, William, Lo-Coco, Francesco, Voso, Maria Teresa, and Ottone, Tiziana
- Published
- 2020
- Full Text
- View/download PDF
10. Detection and management of acute myeloid leukemia measurable residual disease: is it standard of care?
- Author
-
Paterno, Giovangiacinto, Del Principe, Maria Ilaria, and Venditti, Adriano
- Published
- 2020
- Full Text
- View/download PDF
11. Acute leukemia diagnosis during the COVID-19 pandemic
- Author
-
GUARNERA, Luca, primary, BUZZATTI, Elisa, additional, MARCHESI, Francesco, additional, ARMIENTO, Daniele, additional, MAZZONE, Carla, additional, CAPRIA, Saveria, additional, SCALZULLI, Emilia, additional, MALFONA, Francesco, additional, CHIARETTI, Sabina, additional, PALMIERI, Raffaele, additional, PATERNO, Giovangiacinto, additional, FRANZESE, Chiara, additional, BONANNI, Fabrizio, additional, SAVI, Arianna, additional, PASQUALONE, Gianmario, additional, MORETTI, Federico, additional, MAURILLO, Luca, additional, BUCCISANO, Francesco, additional, VENDITTI, Adriano, additional, and DEL PRINCIPE, Maria Ilaria, additional
- Published
- 2023
- Full Text
- View/download PDF
12. Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope
- Author
-
Del Principe, Maria Ilaria, Seidel, Danila, Criscuolo, Marianna, Dargenio, Michelina, Racil, Zdenek, Piedimonte, Monica, Marchesi, Francesco, Nadali, Gianpaolo, Koehler, Philipp, Fracchiolla, Nicola, Cattaneo, Chiara, Klimko, Nikolai, Spolzino, Angelica, Karapinar, Deniz Yilmaz, Demiraslan, Hayati, Duarte, Rafael F., Demeter, Judit, Stanzani, Marta, Melillo, Lorella Maria Antonia, Basilico, Claudia Maria, Cesaro, Simone, Paterno, Giovangiacinto, Califano, Catello, Delia, Mario, Buzzatti, Elisa, Busca, Alessandro, Cornely, Oliver A., Pagano, Livio, Alakel, Nael, Arsenijevi'c, Valentina Arsi'c, Camus, Vincent, Falces-Romero, Iker, Itzhak, Levy, Kouba, Michal, Martino, Rodrigo, Sedlacek, Petr, Weinbergerova, Barbora, Del Principe, Maria Ilaria, Seidel, Danila, Criscuolo, Marianna, Dargenio, Michelina, Racil, Zdenek, Piedimonte, Monica, Marchesi, Francesco, Nadali, Gianpaolo, Koehler, Philipp, Fracchiolla, Nicola, Cattaneo, Chiara, Klimko, Nikolai, Spolzino, Angelica, Karapinar, Deniz Yilmaz, Demiraslan, Hayati, Duarte, Rafael F., Demeter, Judit, Stanzani, Marta, Melillo, Lorella Maria Antonia, Basilico, Claudia Maria, Cesaro, Simone, Paterno, Giovangiacinto, Califano, Catello, Delia, Mario, Buzzatti, Elisa, Busca, Alessandro, Cornely, Oliver A., Pagano, Livio, Alakel, Nael, Arsenijevi'c, Valentina Arsi'c, Camus, Vincent, Falces-Romero, Iker, Itzhak, Levy, Kouba, Michal, Martino, Rodrigo, Sedlacek, Petr, and Weinbergerova, Barbora
- Abstract
Background Our multicentre study aims to identify baseline factors and provide guidance for therapeutic decisions regarding Magnusiomyces-associated infections, an emerging threat in patients with haematological malignancies. Methods HM patients with proven (Magnusiomyces capitatus) M. capitatus or (Magnusiomyces clavatus) M. clavatus (formerly Saprochaete capitata and Saprochaete clavata) infection diagnosed between January 2010 and December 2020 were recorded from the SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group and FungiScope (Global Emerging Fungal Infection Registry). Cases of Magnusiomyces fungemia were compared with candidemia. Results Among 90 Magnusiomyces cases (60 [66%] M. capitatus and 30 (34%) M. clavatus), median age was 50 years (range 2-78), 46 patients (51%) were female and 67 (74%) had acute leukaemia. Thirty-six (40%) of Magnusiomyces-associated infections occurred during antifungal prophylaxis, mainly with posaconazole (n = 13, 36%) and echinocandins (n = 12, 34%). Instead, the candidemia rarely occurred during prophylaxis (p < .0001). First-line antifungal therapy with azoles, alone or in combination, was associated with improved response compared to other antifungals (p = .001). Overall day-30 mortality rate was 43%. Factors associated with higher mortality rates were septic shock (HR 2.696, 95% CI 1.396-5.204, p = .003), corticosteroid treatment longer than 14 days (HR 2.245, 95% CI 1.151-4.376, p = .018) and lack of neutrophil recovery (HR 3.997, 95% CI 2.102-7.601, p < .001). The latter was independently associated with poor outcome (HR 2.495, 95% CI 1.192-5.222, p = .015). Conclusions Magnusiomyces-associated infections are often breakthrough infections. Effective treatment regimens of these infections remain to be determined, but neutrophil recovery appears to play an important role in the favourable outcome.
- Published
- 2023
13. Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
- Author
-
Meddi, Elisa, primary, Savi, Arianna, additional, Moretti, Federico, additional, Mallegni, Flavia, additional, Palmieri, Raffaele, additional, Paterno, Giovangiacinto, additional, Buzzatti, Elisa, additional, Del Principe, Maria Ilaria, additional, Buccisano, Francesco, additional, Venditti, Adriano, additional, and Maurillo, Luca, additional
- Published
- 2023
- Full Text
- View/download PDF
14. FEVER OF UNKNOWN ORIGIN AND MULTIDRUG-RESISTANT ORGANISMS COLONIZATION IN AML PATIENTS.
- Author
-
Guarnera, Luca, primary, Trotta, Gentiana Elena, additional, Boldrini, Valentina, additional, Cardillo, Lucia, additional, Cerroni, Ilaria, additional, Mezzanotte, Valeria, additional, Pasqualone, Gianmario, additional, Savi, Arianna, additional, Borsellino, Beatrice, additional, Buzzatti, Elisa, additional, Palmieri, Raffaele, additional, Paterno, Giovangiacinto, additional, Maurillo, Luca, additional, Buccisano, Francesco, additional, Venditti, Adriano, additional, and Del Principe, Maria Ilaria, additional
- Published
- 2023
- Full Text
- View/download PDF
15. Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia
- Author
-
Palmieri, Raffaele, primary, Maurillo, Luca, additional, Del Principe, Maria Ilaria, additional, Paterno, Giovangiacinto, additional, Walter, Roland Bruno, additional, Venditti, Adriano, additional, and Buccisano, Francesco, additional
- Published
- 2022
- Full Text
- View/download PDF
16. Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope
- Author
-
Weinbergerová, Barbora, Sedlacek, Petr, Martino, Rodrigo, Kouba, Michal, Itzhak, Levy, Falces-Romero, Iker, Camus, Vincent, Arsenijevi'c, Valentina Arsi'c, Alakel, Nael, Pagano, Livio, Cornely, Oliver A., Busca, Alessandro, Buzzatti, Elisa, Delia, Mario, Califano, Catello, Paterno, Giovangiacinto, Cesaro, Simone, Basilico, Claudia Maria, Melillo, Lorella Maria Antonia, Stanzani, Marta, Demeter, Judit, Duarte, Rafael F., Demiraslan, Hayati, Yilmaz Karapinar, Deniz, Spolzino, Angelica, Klimko, Nikolai, Cattaneo, Chiara, Fracchiolla, Nicola, Koehler, Philipp, Nadali, Gianpaolo, Marchesi, Francesco, Piedimonte, Monica, Rácil, Zdenek, Dargenio, Michelina, Criscuolo, Marianna, Seidel, Danila, and Del Principe, Maria Ilaria
- Subjects
Adult ,Male ,Saprochaete ,Antifungal Agents ,Adolescent ,Hematological Malignancies ,Diseases ,Dermatology ,Clavata ,Guidelines ,Young Adult ,Echinocandins ,Trichosporon ,Humans ,Child ,Aged ,Capitatus ,fungal infection ,Candidemia ,General Medicine ,Hematology ,Middle Aged ,Prognosis ,Settore MED/15 ,Geotrichum ,Management ,Settore MED/15 - MALATTIE DEL SANGUE ,antifungal treatment ,Infectious Diseases ,Child, Preschool ,Magnusiomyces ,Invasive Infections ,Female ,Fungal-Infection - Abstract
© 2022 Wiley-VCH GmbH.Background: Our multicentre study aims to identify baseline factors and provide guidance for therapeutic decisions regarding Magnusiomyces-associated infections, an emerging threat in patients with haematological malignancies. Methods: HM patients with proven (Magnusiomyces capitatus) M. capitatus or (Magnusiomyces clavatus) M. clavatus (formerly Saprochaete capitata and Saprochaete clavata) infection diagnosed between January 2010 and December 2020 were recorded from the SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group and FungiScope (Global Emerging Fungal Infection Registry). Cases of Magnusiomyces fungemia were compared with candidemia. Results: Among 90 Magnusiomyces cases (60 [66%] M. capitatus and 30 (34%) M. clavatus), median age was 50 years (range 2–78), 46 patients (51%) were female and 67 (74%) had acute leukaemia. Thirty-six (40%) of Magnusiomyces-associated infections occurred during antifungal prophylaxis, mainly with posaconazole (n = 13, 36%) and echinocandins (n = 12, 34%). Instead, the candidemia rarely occurred during prophylaxis (p
- Published
- 2022
17. Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience
- Author
-
Paterno, Giovangiacinto, primary, Palmieri, Raffaele, additional, Forte, Vittorio, additional, Del Prete, Valentina, additional, Gurnari, Carmelo, additional, Guarnera, Luca, additional, Mallegni, Flavia, additional, Pascale, Maria Rosaria, additional, Buzzatti, Elisa, additional, Mezzanotte, Valeria, additional, Cerroni, Ilaria, additional, Savi, Arianna, additional, Buccisano, Francesco, additional, Maurillo, Luca, additional, Venditti, Adriano, additional, and Del Principe, Maria Ilaria, additional
- Published
- 2022
- Full Text
- View/download PDF
18. Real Life Feasibility of a Combined Clinical and Biological Fitness Assessment in Patients with Acute Myeloid Leukemia
- Author
-
Palmieri, Raffaele, primary, Iacobelli, Simona, additional, Paterno, Giovangiacinto, additional, Federico, Moretti, additional, Buzzatti, Elisa, additional, Elisa, Meddi, additional, Arianna, Savi, additional, Trotta, Gentiana, additional, Mallegni, Flavia, additional, Del Principe, Maria Ilaria, additional, Maurillo, Luca, additional, Voso, Maria Teresa, additional, Venditti, Adriano, additional, and Buccisano, Francesco, additional
- Published
- 2022
- Full Text
- View/download PDF
19. Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia
- Author
-
Palmieri, Raffaele, primary, Othus, Megan, additional, Cheng, Guang-Shing, additional, Buccisano, Francesco, additional, Paterno, Giovangiacinto, additional, Maurillo, Luca, additional, Del Principe, Maria Ilaria, additional, Sconocchia, Giuseppe, additional, Venditti, Adriano, additional, and Walter, Roland B., additional
- Published
- 2022
- Full Text
- View/download PDF
20. In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia
- Author
-
Buzzatti, Elisa, primary, Forghieri, Fabio, additional, Paterno, Giovangiacinto, additional, Marchesi, Francesco, additional, Sarlo, Chiara, additional, Giglio, Fabio, additional, Fracchiolla, Nicola, additional, Sciumè, Mariarita, additional, Palmieri, Raffaele, additional, Esposito, Fabiana, additional, Guarnera, Luca, additional, Mercante, Lisa, additional, Pascale, Maria Rosaria, additional, Mallegni, Flavia, additional, Savi, Arianna, additional, Forte, Vittorio, additional, Maurillo, Luca, additional, Buccisano, Francesco, additional, Venditti, Adriano, additional, and Del Principe, Maria Ilaria, additional
- Published
- 2022
- Full Text
- View/download PDF
21. Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial
- Author
-
Buccisano, Francesco, primary, Palmieri, Raffaele, additional, Piciocchi, Alfonso, additional, Arena, Valentina, additional, Maurillo, Luca, additional, Del Principe, Maria-Ilaria, additional, Paterno, Giovangiacinto, additional, Irno-Consalvo, Maria-Antonietta, additional, Ottone, Tiziana, additional, Divona, Mariadomenica, additional, Conti, Consuelo, additional, Fraboni, Daniela, additional, Lavorgna, Serena, additional, Arcese, William, additional, Voso, Maria Teresa, additional, and Venditti, Adriano, additional
- Published
- 2022
- Full Text
- View/download PDF
22. Occult central nervous system involvement guides therapeutic choices in blastic plasmacytoid dendritic cell neoplasms
- Author
-
Buzzatti, Elisa, primary, Paterno, Giovangiacinto, additional, Palmieri, Raffaele, additional, Esposito, Fabiana, additional, Pascale, Maria Rosaria, additional, Mallegni, Flavia, additional, Guarnera, Luca, additional, Pasqualone, Gianmario, additional, Irno Consalvo, Maria Antonietta, additional, Fraboni, Daniela, additional, Moretti, Federico, additional, Savi, Arianna, additional, Borsellino, Beatrice, additional, Maurillo, Luca, additional, Buccisano, Francesco, additional, Sconocchia, Giuseppe, additional, Venditti, Adriano, additional, and Del Principe, Maria Ilaria, additional
- Published
- 2022
- Full Text
- View/download PDF
23. Pneumocystis jirovecii pneumonia in patients with previously untreated acute myeloid leukaemia
- Author
-
Paterno, Giovangiacinto, primary, Guarnera, Luca, additional, Palmieri, Raffaele, additional, Del Prete, Valentina, additional, Bonanni, Fabrizio, additional, Buzzatti, Elisa, additional, Moretti, Federico, additional, Casciani, Paola, additional, Savi, Arianna, additional, Di Cave, David, additional, Maurillo, Luca, additional, Buccisano, Francesco, additional, Venditti, Adriano, additional, and Del Principe, Maria Ilaria, additional
- Published
- 2021
- Full Text
- View/download PDF
24. Therapy-related Myeloid Neoplasms: Considerations for Patients' Clinical Evaluation.
- Author
-
Palmieri, Raffaele, Paterno, Giovangiacinto, Mallegni, Flavia, Frenza, Federica, De Bernardis, Ilenia, Moretti, Federico, Meddi, Elisa, Ilaria Del Principe, Maria, Maurillo, Luca, Venditti, Adriano, and Buccisano, Francesco
- Subjects
- *
GENETIC profile , *TUMORS , *THERAPEUTICS , *ACUTE myeloid leukemia - Abstract
Therapy-related myeloid neoplasms (t-MNs) encompass a specific sub-group of myeloid malignancies arising after exposure to radio/cytotoxic agents for the treatment of unrelated diseases. Such malignancies present unique features, including advanced age, high comorbidities burden, and unfavorable genetic profiles. All these features justify the need for a specific diagnostic workup and dedicated treatment algorithms. However, as new classification systems recognize the unique clinical characteristics exhibited by t-MN patients, how to assess fitness status in this clinical setting is largely unexplored. Optimizing fitness assessment would be crucial in the management of t-MN patients, considering that factors usually contributing to a worse or better outcome (like age, comorbidities, and treatment history) are patient-specific. In the absence of specific tools for fitness assessment in this peculiar category of AML, the aim of this review is to describe all those factors related to patient, treatment, and disease that allow planning treatments with an optimal risk/benefit ratio. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia.
- Author
-
Palmieri, Raffaele, Maurillo, Luca, Del Principe, Maria Ilaria, Paterno, Giovangiacinto, Walter, Roland Bruno, Venditti, Adriano, and Buccisano, Francesco
- Subjects
PHYSICAL fitness - Published
- 2023
- Full Text
- View/download PDF
26. CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia
- Author
-
Palmieri, Raffaele, primary, Buccisano, Francesco, additional, Arena, Valentina, additional, Irno Consalvo, Maria Antonietta, additional, Piciocchi, Alfonso, additional, Maurillo, Luca, additional, DelPrincipe, Maria Ilaria, additional, Di Veroli, Ambra, additional, Paterno, Giovangiacinto, additional, Conti, Consuelo, additional, Fraboni, Daniela, additional, Voso, Maria Teresa, additional, Arcese, William, additional, and Venditti, Adriano, additional
- Published
- 2021
- Full Text
- View/download PDF
27. Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia
- Author
-
Venditti, Adriano, primary, Piciocchi, Alfonso, additional, Palmieri, Raffaele, additional, Arena, Valentina, additional, Candoni, Anna, additional, Calafiore, Valeria, additional, Melillo, Lorella MA, additional, Cairoli, Roberto, additional, De Fabritiis, Paolo, additional, Storti, Gabriella, additional, Salutari, Prassede, additional, Lanza, Francesco, additional, Martinelli, Giovanni, additional, Luppi, Mario, additional, Capria, Saveria, additional, Maurillo, Luca, additional, Del Principe, Maria Ilaria, additional, Paterno, Giovangiacinto, additional, Buzzatti, Elisa, additional, Voso, Maria Teresa, additional, Ottone, Tiziana, additional, irno Consalvo, Maria, additional, Fazi, Paola, additional, Vignetti, Marco, additional, Arcese, William, additional, Amadori, Sergio, additional, and Buccisano, Francesco, additional
- Published
- 2021
- Full Text
- View/download PDF
28. Prevalence and Genotyping of Pneumocystis jirovecii Pneumonia in Patients with Previously Untreated Acute Myeloid Leukemia
- Author
-
Prete, Valentina Del, primary, Paterno, Giovangiacinto, additional, Di Cave, David, additional, Guarnera, Luca, additional, Palmieri, Raffaele, additional, Maurillo, Luca, additional, Buccisano, Francesco, additional, Venditti, Adriano, additional, and Del Principe, Maria Ilaria, additional
- Published
- 2021
- Full Text
- View/download PDF
29. COVID-19 infection in adult patients with hematological malignancies:a European Hematology Association Survey (EPICOVIDEHA)
- Author
-
Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Verga, Luisa, Víšek, Benjamin, Ilhan, Osman, Nadali, Gianpaolo, Weinbergerová, Barbora, Córdoba-Mascuñano, Raúl, Marchetti, Monia, Collins, Graham P., Farina, Francesca, Cattaneo, Chiara, Cabirta, Alba, Gomes-Silva, Maria, Itri, Federico, van Doesum, Jaap, Ledoux, Marie-Pierre, Čerňan, Martin, Jakšić, Ozren, Duarte, Rafael F., Magliano, Gabriele, Omrani, Ali S., Fracchiolla, Nicola S., Kulasekararaj, Austin, Valković, Toni, Poulsen, Christian Bjørn, Machado, Marina, Glenthøj, Andreas, Stoma, Igor, Ráčil, Zdeněk, Piukovics, Klára, Navrátil, Milan, Emarah, Ziad, Sili, Uluhan, Maertens, Johan, Blennow, Ola, Bergantim, Rui, García-Vidal, Carolina, Prezioso, Lucia, Guidetti, Anna, del Principe, Maria Ilaria, Popova, Marina, de Jonge, Nick, Ormazabal-Vélez, Irati, Fernández, Noemí, Falces-Romero, Iker, Cuccaro, Annarosa, Meers, Stef, Buquicchio, Caterina, Antić, Darko, Al-Khabori, Murtadha, García-Sanz, Ramón, Biernat, Monika M., Tisi, Maria Chiara, Sal, Ertan, Rahimli, Laman, Čolović, Natasa, Schönlein, Martin, Calbacho, Maria, Tascini, Carlo, Miranda-Castillo, Carolina, Khanna, Nina, Méndez, Gustavo-Adolfo, Petzer, Verena, Novák, Jan, Besson, Caroline, Duléry, Rémy, Lamure, Sylvain, Nucci, Marcio, Zambrotta, Giovanni, Žák, Pavel, Seval, Guldane Cengiz, Bonuomo, Valentina, Mayer, Jiří, López-García, Alberto, Sacchi, Maria Vittoria, Booth, Stephen, Ciceri, Fabio, Oberti, Margherita, Salvini, Marco, Izuzquiza, Macarena, Nunes-Rodrigues, Raquel, Ammatuna, Emanuele, Obr, Aleš, Herbrecht, Raoul, Núñez-Martín-Buitrago, Lucía, Mancini, Valentina, Shwaylia, Hawraa, Sciumè, Mariarita, Essame, Jenna, Nygaard, Marietta, Batinić, Josip, Gonzaga, Yung, Regalado-Artamendi, Isabel, Karlsson, Linda Katharina, Shapetska, Maryia, Hanakova, Michaela, El-Ashwah, Shaimaa, Borbényi, Zita, Çolak, Gökçe Melis, Nordlander, Anna, Dragonetti, Giulia, Maraglino, Alessio Maria Edoardo, Rinaldi, Amelia, De Ramón-Sánchez, Cristina, Cornely, Oliver A., Finizio, Olimpia, Fazzi, Rita, Sapienza, Giuseppe, Chauchet, Adrien, Van Praet, Jens, Prattes, Juergen, Dargenio, Michelina, Rossi, Cédric, Shirinova, Ayten, Malak, Sandra, Tafuri, Agostino, Ommen, Hans-Beier, Bologna, Serge, Khedr, Reham Abdelaziz, Choquet, Sylvain, Joly, Bertrand, Ceesay, M. Mansour, Philippe, Laure, Kho, Chi Shan, Desole, Maximilian, Tsirigotis, Panagiotis, Otašević, Vladimir, Borducchi, Davimar M. M., Antoniadou, Anastasia, Gaziev, Javid, Almaslamani, Muna A., García-Poutón, Nicole, Paterno, Giovangiacinto, Torres-López, Andrea, Tarantini, Giuseppe, Mellinghoff, Sibylle, Gräfe, Stefanie, Börschel, Niklas, Passweg, Jakob, Merelli, Maria, Barać, Aleksandra, Wolf, Dominik, Shaikh, Mohammad Usman, Thiéblemont, Catherine, Bernard, Sophie, Funke, Vaneuza Araújo Moreira, Daguindau, Etienne, Khostelidi, Sofya, Nucci, Fabio Moore, Martín-González, Juan-Alberto, Landau, Marianne, Soussain, Carole, Laureana, Cécile, Lacombe, Karine, Kohn, Milena, Aliyeva, Gunay, Piedimonte, Monica, Fouquet, Guillemette, Rêgo, Mayara, Hoell-Neugebauer, Baerbel, Cartron, Guillaume, Pinto, Fernando, Alburquerque, Ana Munhoz, Passos, Juliana, Yilmaz, Asu Fergun, Redondo-Izal, Ana-Margarita, Altuntaş, Fevzi, Heath, Christopher, Kolditz, Martin, Schalk, Enrico, Guolo, Fabio, Karthaus, Meinolf, Della Pepa, Roberta, Vinh, Donald, Noël, Nicolas, Deau Fischer, Bénédicte, Drenou, Bernard, Mitra, Maria Enza, Meletiadis, Joseph, Bilgin, Yavuz M., Jindra, Pavel, Espigado, Ildefonso, Drgoňa, Ľuboš, Serris, Alexandra, Di Blasi, Roberta, Ali, Natasha, EPICOVIDEHA working group, [missing], Pagano, Livio, Salmanton-Garcia, Jon, Marchesi, Francesco, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Verga, Luisa, Visek, Benjamin, Ilhan, Osman, Nadali, Gianpaolo, Weinbergerova, Barbora, Cordoba-Mascunano, Raul, Marchetti, Monia, Collins, Graham P., Farina, Francesca, Cattaneo, Chiara, Cabirta, Alba, Gomes-Silva, Maria, Itri, Federico, van Doesum, Jaap, Ledoux, Marie-Pierre, Cernan, Martin, Jaksic, Ozren, Duarte, Rafael F., Magliano, Gabriele, Omrani, Ali S., Fracchiolla, Nicola S., Kulasekararaj, Austin, Valkovic, Toni, Poulsen, Christian Bjorn, Machado, Marina, Glenthoj, Andreas, Stoma, Igor, Racil, Zdenek, Piukovics, Klara, Navratil, Milan, Emarah, Ziad, Sili, Uluhan, Maertens, Johan, Blennow, Ola, Bergantim, Rui, Garcia-Vidal, Carolina, Prezioso, Lucia, Guidetti, Anna, del Principe, Maria Ilaria, Popova, Marina, de Jonge, Nick, Ormazabal-Velez, Irati, Fernandez, Noemi, Falces-Romero, Iker, Cuccaro, Annarosa, Meers, Stef, Buquicchio, Caterina, Antic, Darko, Al-Khabori, Murtadha, Garcia-Sanz, Ramon, Biernat, Monika M., Tisi, Maria Chiara, Sal, Ertan, Rahimli, Laman, Colovic, Natasa, Schonlein, Martin, Calbacho, Maria, Tascini, Carlo, Miranda-Castillo, Carolina, Khanna, Nina, Mendez, Gustavo-Adolfo, Petzer, Verena, Novak, Jan, Besson, Caroline, Dulery, Remy, Lamure, Sylvain, Nucci, Marcio, Zambrotta, Giovanni, Zak, Pavel, Seval, Guldane Cengiz, Bonuomo, Valentina, Mayer, Jiri, Lopez-Garcia, Alberto, Sacchi, Maria Vittoria, Booth, Stephen, Ciceri, Fabio, Oberti, Margherita, Salvini, Marco, Izuzquiza, Macarena, Nunes-Rodrigues, Raquel, Ammatuna, Emanuele, Obr, Ales, Herbrecht, Raoul, Nunez-Martin-Buitrago, Lucia, Mancini, Valentina, Shwaylia, Hawraa, Sciume, Mariarita, Essame, Jenna, Nygaard, Marietta, Batinic, Josip, Gonzaga, Yung, Regalado-Artamendi, Isabel, Karlsson, Linda Katharina, Shapetska, Maryia, Hanakova, Michaela, El-Ashwah, Shaimaa, Borbenyi, Zita, Colak, Gokce Melis, Nordlander, Anna, Dragonetti, Giulia, Maraglino, Alessio Maria Edoardo, Rinaldi, Amelia, De Ramon-Sanchez, Cristina, Cornely, Oliver A., Pagano, L., Salmanton-Garcia, J., Marchesi, F., Busca, A., Corradini, P., Hoenigl, M., Klimko, N., Koehler, P., Pagliuca, A., Passamonti, F., Verga, L., Visek, B., Ilhan, O., Nadali, G., Weinbergerova, B., Cordoba-Mascunano, R., Marchetti, M., Collins, G. P., Farina, F., Cattaneo, C., Cabirta, A., Gomes-Silva, M., Itri, F., van Doesum, J., Ledoux, M. -P., Cernan, M., Jaksic, O., Duarte, R. F., Magliano, G., Omrani, A. S., Fracchiolla, N. S., Kulasekararaj, A., Valkovic, T., Poulsen, C. B., Machado, M., Glenthoj, A., Stoma, I., Racil, Z., Piukovics, K., Navratil, M., Emarah, Z., Sili, U., Maertens, J., Blennow, O., Bergantim, R., Garcia-Vidal, C., Prezioso, L., Guidetti, A., del Principe, M. I., Popova, M., de Jonge, N., Ormazabal-Velez, I., Fernandez, N., Falces-Romero, I., Cuccaro, A., Meers, S., Buquicchio, C., Antic, D., Al-Khabori, M., Garcia-Sanz, R., Biernat, M. M., Tisi, M. C., Sal, E., Rahimli, L., Colovic, N., Schonlein, M., Calbacho, M., Tascini, C., Miranda-Castillo, C., Khanna, N., Mendez, G. -A., Petzer, V., Novak, J., Besson, C., Dulery, R., Lamure, S., Nucci, M., Zambrotta, G., Zak, P., Seval, G. C., Bonuomo, V., Mayer, J., Lopez-Garcia, A., Sacchi, M. V., Booth, S., Ciceri, F., Oberti, M., Salvini, M., Izuzquiza, M., Nunes-Rodrigues, R., Ammatuna, E., Obr, A., Herbrecht, R., Nunez-Martin-Buitrago, L., Mancini, V., Shwaylia, H., Sciume, M., Essame, J., Nygaard, M., Batinic, J., Gonzaga, Y., Regalado-Artamendi, I., Karlsson, L. K., Shapetska, M., Hanakova, M., El-Ashwah, S., Borbenyi, Z., Colak, G. M., Nordlander, A., Dragonetti, G., Maraglino, A. M. E., Rinaldi, A., De Ramon-Sanchez, C., Cornely, O. A., Finizio, O., Fazzi, R., Sapienza, G., Chauchet, A., Van Praet, J., Prattes, J., Dargenio, M., Rossi, C., Shirinova, A., Malak, S., Tafuri, A., Ommen, H. -B., Bologna, S., Khedr, R. A., Choquet, S., Joly, B., Ceesay, M. M., Philippe, L., Kho, C. S., Desole, M., Tsirigotis, P., Otasevic, V., Borducchi, D. M. M., Antoniadou, A., Gaziev, J., Almaslamani, M. A., Garcia-Pouton, N., Paterno, G., Torres-Lopez, A., Tarantini, G., Mellinghoff, S., Grafe, S., Borschel, N., Passweg, J., Merelli, M., Barac, A., Wolf, D., Shaikh, M. U., Thieblemont, C., Bernard, S., Funke, V. A. M., Daguindau, E., Khostelidi, S., Nucci, F. M., Martin-Gonzalez, J. -A., Landau, M., Soussain, C., Laureana, C., Lacombe, K., Kohn, M., Aliyeva, G., Piedimonte, M., Fouquet, G., Rego, M., Hoell-Neugebauer, B., Cartron, G., Pinto, F., Alburquerque, A. M., Passos, J., Yilmaz, A. F., Redondo-Izal, A. -M., Altuntas, F., Heath, C., Kolditz, M., Schalk, E., Guolo, F., Karthaus, M., Della Pepa, R., Vinh, D., Noel, N., Deau Fischer, B., Drenou, B., Mitra, M. E., Meletiadis, J., Bilgin, Y. M., Jindra, P., Espigado, I., Drgona, L., Serris, A., Di Blasi, R., Ali, N., Stem Cell Aging Leukemia and Lymphoma (SALL), Salvy-Córdoba, Nathalie, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), University Hospital of Cologne [Cologne], Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, IFO - Istituto Nazionale Tumori Regina Elena [Roma] (IRE), Città della Salute e della Scienza University-Hospital, IRCCS Istituto Nazionale dei Tumori [Milano], University of California [San Diego] (UC San Diego), University of California (UC), Medical University of Graz, Odessa National I.I.Mechnikov University, Faculty of Medicine [Cologne], University Hospital of Cologne [Cologne]-University of Cologne, King's College Hospital (KCH), Universitá degli Studi dell’Insubria = University of Insubria [Varese] (Uninsubria), Dipartimento di Medicina e Chirurgia = School of Medicine and Surgery [Monza], Università degli Studi di Milano-Bicocca = University of Milano-Bicocca (UNIMIB), Faculty of Medicine in Hradec Kralove [Republique Tchèque], Charles University [Prague] (CU), Ankara University School of Medicine [Turkey], Azienda Ospedaliera Universitaria Integrata of Verona, Masaryk University [Brno] (MUNI), Fundación Jiménez Díaz, Fundacion Jimenez Diaz [Madrid] (FJD), Ospedale SS Antonio e Biagio e Cesare Arrigo, Churchill Hospital Oxford Centre for Haematology, IRCCS San Raffaele Scientific Institute [Milan, Italie], ASST Spedali Civili of Brescia, Vall d'Hebron Institute of Oncology [Barcelone] (VHIO), Vall d'Hebron University Hospital [Barcelona], Universitat Autònoma de Barcelona (UAB), Instituto Português de Oncologia de Lisboa Francisco Gentil, Ospedale San Luigi Gonzaga, University Medical Center Groningen [Groningen] (UMCG), Institut de Cancérologie de Strasbourg Europe (ICANS), Palacky University Olomouc, Zagreb School of Medicine [Zagreb, Croatia] (Dubrava University Hospital), University of Zagreb, Hospital Universitario Puerta de Hierro-Majadahonda [Madrid, Spain], ASST Great Metropolitan Niguarda / ASST Grande Ospedale Metropolitano Niguarda [Milan, Italia], Hamad Medical Corporation [Doha, Qatar], Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, University of Rijeka, Croatian Cooperative Group for Hematological Diseases (CROHEM), Zealand University Hospital [Roskilde, Denmark], Hospital General Universitario 'Gregorio Marañón' [Madrid], Department of Clinical Microbiology [Rigshospitalet], Rigshospitalet [Copenhagen], Copenhagen University Hospital-Copenhagen University Hospital, Homieĺ State Medical University (GSMU), Institute of Hematology and Blood Transfusion [Prague, Czech Republic], University of Szeged [Szeged], University Hospital Ostrava, Mansoura University [Egypt], Marmara University [Kadıköy - İstanbul], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Karolinska University Hospital [Stockholm], Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto = University of Porto, Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Hospital de São João [Porto], Faculdade de Medicina da Universidade do Porto (FMUP), Clinic Barcelona Hospital Universitari, Department of Public Health and Cell Biology, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy, Pavlov First Saint Petersburg State Medical University [St. Petersburg], Vrije Universiteit Medical Centre (VUMC), Vrije Universiteit Amsterdam [Amsterdam] (VU), Complejo Hospitalario de Navarra, Hospital Universitario Marqués de Valdecilla [Santander], La Paz University Hospital, Azienda Usl Toscana centro [Firenze], AZ Klina, Clinical Center of Serbia (KCS), University of Belgrade [Belgrade], Sultan Qaboos University Hospital, Partenaires INRAE, Hospital Universitario de Salamanca, Servicio de Haematologia, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), University of Wrocław [Poland] (UWr), San Bortolo Hospital, Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), Hospital Universitario 12 de Octubre [Madrid], Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), Universidad Rey Juan Carlos [Madrid] (URJC), University of Basel (Unibas), Innsbruck Medical University = Medizinische Universität Innsbruck (IMU), University Hospital Kralovské Vinohrady, Centre Hospitalier de Versailles André Mignot (CHV), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Département Hématologie biologique [CHRU Montpellier], Pôle Biologie-Pathologie [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Universidade Federal do Estado do Rio de Janeiro (UNIRIO), San Gerardo Hospital of Monza, Oxford NIHR Biomedical Research Centre, IRCCS Ospedale San Raffaele [Milan, Italy], Assi Sette Llaghi Varese, Instituto Português de Oncologia do Porto / Portuguese Oncology Institute of Porto (IPO Porto), University Hospital Olomouc [Czech Republic], ASST Grande Ospedale Metropolitano Niguarda, University Hospital Centre Zagreb, Instituto Nacional do Câncer, Copenhagen University Hospital, Republican Scientific and Practical Center (RSPC) for organ and Tissue Transplantation, Minsk, Republican Scientific and Practical Center (RSPC) for Organ and Transplantation, German Centre for Infection Research (DZIF), Gilead Sciences, Pagano, Livio [0000-0001-8287-928X], Salmanton-García, Jon [0000-0002-6766-8297], Marchesi, Francesco [0000-0001-6353-2272], Busca, Alessandro [0000-0001-5361-5613], Corradini, Paolo [0000-0002-9186-1353], Hoenigl, Martin [0000-0002-1653-2824], Klimko, Nikolay [0000-0001-6095-7531], Koehler, Philipp [0000-0002-7386-7495], Pagliuca, Antonio [0000-0003-2519-0333], Passamonti, Francesco [0000-0001-8068-5289], Verga, Luisa [0000-0003-1142-8435], Víšek, Benjamin [0000-0001-8268-452X], Ilhan, Osman [0000-0003-1665-372X], Weinbergerová, Barbora [0000-0001-6460-2471], Córdoba, Raúl [0000-0002-7654-8836], Marchetti, Monia [0000-0001-7615-0572], Farina, Francesca [0000-0002-5124-6970], Cattaneo, Chiara [0000-0003-0031-3237], Cabirta, Alba [0000-0001-7198-8894], Gomes-Silva, Maria [0000-0002-6993-2450], Itri, Federico [0000-0002-3532-5281], Doesum, Jaap van [0000-0003-0214-3219], Ledoux, Marie-Pierre [0000-0002-3261-3616], Čerňan, Martin [0000-0003-2345-1229], Jakšić, Ozren [0000-0003-4026-285X], Magliano, Gabriel [0000-0002-9129-1530], Omrani, Ali S. [0000-0001-5309-6358], Fracchiolla, Nicola S. [0000-0002-8982-8079], Kulasekararaj, Austin G. [0000-0003-3180-3570], Valković, Toni [0000-0001-6083-8815], Poulsen, Christian Bjørn [0000-0001-9785-1378], Machado, Marina [0000-0002-8370-2248], Glenthøj, Andrea [0000-0003-2082-0738], Stoma, Igor [0000-0003-0483-7329], Ráčil, Zdeněk [0000-0003-3511-4596], Piukovics, Klára [0000-0003-4480-3131], Emarah, Ziad [0000-0003-0622-2598], Sili, Uluhan [0000-0002-9939-9298], Maertens, Johan [0000-0003-4257-5980], Bergantim, Rui [0000-0002-7811-9509], García-Vidal, Carolina [0000-0002-8915-0683], Prezioso, Lucia [0000-0003-1660-4960], Principe, Maria Ilaria del [0000-0002-3958-0669], Popova, Marina [0000-0001-8536-5495], Jonge, Nick de [0000-0002-9901-0887], Ormazabal-Vélez, Irati [0000-0003-1141-5546], Falces-Romero, Iker [0000-0001-5888-7706], Cuccaro, Annarosa [0000-0002-0237-1839], Meers, Stef [0000-0003-1754-2175], Buquicchio, Caterina [0000-0002-3683-5953], Antić, Darko [0000-0002-2608-1342], Al-Khabori, Murtadha [0000-0002-2937-8838], García-Sanz, Ramón [0000-0003-4120-2787], Biernat, Monika [0000-0003-3161-3398], Tisi, Maria Chiara [0000-0001-8231-6700], Sal, Ertan [0000-0003-2761-2675], Rahimli, Laman [0000-0003-2266-445X], Schönlein, Martin [0000-0002-1010-0975], Calbacho, María [0000-0001-8106-4863], Tascini, Carlo [0000-0001-9625-6024], Miranda-Castillo, Carolina [0000-0001-8763-9576], Khanna, Nina [0000-0002-2642-419X], Méndez, Gustavo-Adolfo [0000-0003-0514-7004], Petzer, Verena [0000-0002-9205-1440], Besson, Caroline [0000-0003-4364-7173], Duléry, Rémy [0000-0002-5024-1713], Lamure, Sylvain [0000-0001-5980-305X], Nucci, Marcio [0000-0003-4867-0014], Zambrotta, Giovanni [0000-0002-8612-2994], Žák, Pavel [0000-0003-4465-5343], Cengiz Seval, Guldane [0000-0001-9433-2054], Bonuomo, Valentina [0000-0001-6491-8337], Mayer, Jiří [0000-0003-0567-9887], López-García, Alberto [0000-0002-5354-5261], Sacchi, Maria Vittoria [0000-0001-8133-3357], Booth, Stephen [0000-0003-2687-0234], Ciceri, Fabio [0000-0003-0873-0123], Nunes-Rodrigues, Raquel [0000-0002-8347-4281], Ammatuna, Emanuele [0000-0001-8247-4901], Obr, Aleš [0000-0002-6758-3074], Herbrecht, Raoul [0000-0002-9381-4876], Shwaylia, Hawraa [0000-0002-4098-6092], Sciumè, Mariarita [0000-0001-7958-4966], Essame, Jenna [0000-0003-0926-5577], Batinić, Josip [0000-0001-5595-9911], Gonzaga, Yung [0000-0003-1416-2118], Regalado-Artamendi, Isabel [0000-0002-9673-9015], Karlsson, Linda Katharina [0000-0003-3317-7550], Shapetska, Maryia [0000-0002-1223-9161], El-Ashwah, Shaimaa [0000-0003-2210-1534], Çolak, Gökçe Melis [0000-0002-7662-7454], Dragonetti, Giulia [0000-0003-1775-6333], Rinaldi, Amelia [0000-0002-8211-5076], Ramón, Cristina de [0000-0002-8167-6410], Cornely, Oliver A. [0000-0001-9599-3137], Institut Català de la Salut, [Pagano L] Hematology, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS – Università Cattolica del Sacro Cuore, Rome, Italy. Università Cattolica del Sacro Cuore, Rome, Italy. [Salmanton-García J] Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Excellence Center for Medical Mycology (ECMM), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. Cologne Excellence Cluster On Cellular Stress Responses in Aging Associated Diseases (CECAD), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. [Marchesi F] Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. [Busca A] Stem Cell Transplant Center, AOU Citta’ Della Salute E Della Scienza, Turin, Italy. [Corradini P] University of Milan and Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. [Hoenigl M] Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA, USA. Clinical and Translational Fungal Working Group, University of California San Diego, La Jolla, CA, USA. Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Graz, Austria. [Cabirta A, Izuzquiza M] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, Hematology, Salmanton-García, Jon, Klimko, Nikolay, Víšek, Benjamin, Weinbergerová, Barbora, Córdoba, Raúl, Doesum, Jaap van, Čerňan, Martin, Jakšić, Ozren, Magliano, Gabriel, Kulasekararaj, Austin G., Valković, Toni, Poulsen, Christian Bjørn, Glenthøj, Andrea, Ráčil, Zdeněk, Piukovics, Klára, García-Vidal, Carolina, Principe, Maria Ilaria del, Jonge, Nick de, Ormazabal-Vélez, Irati, Antić, Darko, García-Sanz, Ramón, Biernat, Monika, Schönlein, Martin, Calbacho, María, Méndez, Gustavo-Adolfo, Duléry, Rémy, Žák, Pavel, Cengiz Seval, Guldane, Mayer, Jiří, López-García, Alberto, Obr, Aleš, Sciumè, Mariarita, Batinić, Josip, Çolak, Gökçe Melis, Ramón, Cristina de, and Universidad de Sevilla. Departamento de Medicina
- Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology ,Male ,Cancer Research ,MESH: Registries ,Epidemiology ,MESH: Hospitalization ,Hematological malignancies ,Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores] ,MESH: Aged, 80 and over ,MESH: Risk Factors ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Risk Factors ,Malalties - Factors de risc ,Risk of mortality ,Medicine and Health Sciences ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,80 and over ,Medicine ,MESH: COVID-19 ,Registries ,Sang - Malalties - Complicacions ,RC254-282 ,Cause of death ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina ,MESH: Aged ,Aged, 80 and over ,Hematology ,MESH: Middle Aged ,Mortality rate ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Myeloid leukemia ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Middle Aged ,CANCER ,Europe ,Hospitalization ,Intensive Care Units ,Oncology ,MESH: Young Adult ,Hematologic Neoplasms ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Female ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Infektologija ,Life Sciences & Biomedicine ,Adult ,medicine.medical_specialty ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,COVID-19 ,EHA ,Pandemic ,Aged ,Humans ,SARS-CoV-2 ,Young Adult ,técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Intensive care ,Internal medicine ,Diseases of the blood and blood-forming organs ,MESH: SARS-CoV-2 ,neoplasias::neoplasias por localización::neoplasias hematológicas [ENFERMEDADES] ,Molecular Biology ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine ,pandemic ,hematological malignancies ,epidemiology ,MESH: Humans ,Science & Technology ,business.industry ,Myelodysplastic syndromes ,Research ,MESH: Adult ,Neoplasms::Neoplasms by Site::Hematologic Neoplasms [DISEASES] ,medicine.disease ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Infectology ,Settore MED/15 ,MESH: Male ,Settore MED/15 - MALATTIE DEL SANGUE ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,COVID-19 (Malaltia) - Diagnòstic ,MESH: Intensive Care Units ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,MESH: Europe ,RC633-647.5 ,business ,MESH: Female ,Other subheadings::Other subheadings::/complications [Other subheadings] ,MESH: Hematologic Neoplasms - Abstract
Background Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value, EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223).
- Published
- 2021
30. Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation
- Author
-
Buccisano, Francesco, primary, Palmieri, Raffaele, additional, Piciocchi, Alfonso, additional, Maurillo, Luca, additional, Del Principe, Maria Ilaria, additional, Paterno, Giovangiacinto, additional, Soddu, Stefano, additional, Cerretti, Raffaella, additional, De Angelis, Gottardo, additional, Mariotti, Benedetta, additional, Irno Consalvo, Maria Antonietta, additional, Conti, Consuelo, additional, Fraboni, Daniela, additional, Divona, Mariadomenica, additional, Ottone, Tiziana, additional, Lavorgna, Serena, additional, Panetta, Paola, additional, Voso, Maria Teresa, additional, Arcese, William, additional, and Venditti, Adriano, additional
- Published
- 2021
- Full Text
- View/download PDF
31. CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia.
- Author
-
Palmieri, Raffaele, Buccisano, Francesco, Arena, Valentina, Irno Consalvo, Maria Antonietta, Piciocchi, Alfonso, Maurillo, Luca, DelPrincipe, Maria Ilaria, Di Veroli, Ambra, Paterno, Giovangiacinto, Conti, Consuelo, Fraboni, Daniela, Voso, Maria Teresa, Arcese, William, and Venditti, Adriano
- Subjects
ACUTE myeloid leukemia ,PRELEUKEMIA ,STEM cells ,FLOW cytometry ,CD34 antigen ,BIOMARKERS - Abstract
The absence of measurable residual disease (MRD) in morphologic complete remission (CR) represents a favorable prognosticator in acute myeloid leukemia (AML) [[1]]. At the diagnostic evaluation, patients were defined as LSCs negative (LSC-0) in case of undetectable LSCs count, LSC SP low sp and LSC SP high sp when LSCs were detected below or above a threshold of 0.03%, respectively [[4]]. Indeed, patients with a high LSC burden at diagnosis have an unfavorable outcome unless LSCs are cleared by chemotherapy. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
32. Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol
- Author
-
Palmieri, Raffaele, primary, Buccisano, Francesco, additional, Piciocchi, Alfonso, additional, Arena, Valentina, additional, Candoni, Anna, additional, Melillo, Lorella MA, additional, Calafiore, Valeria, additional, Cairoli, Roberto, additional, De Fabritiis, Paolo, additional, Storti, Gabriella, additional, Salutari, Prassede, additional, Lanza, Francesco, additional, Martinelli, Giovanni, additional, Luppi, Mario, additional, Capria, Saveria, additional, Maurillo, Luca, additional, Del Principe, Maria Ilaria, additional, Paterno, Giovangiacinto, additional, Voso, Maria Teresa, additional, Ottone, Tiziana, additional, Lavorgna, Serena, additional, Fazi, Paola, additional, Vignetti, Marco, additional, Arcese, William, additional, and Venditti, Adriano, additional
- Published
- 2020
- Full Text
- View/download PDF
33. Clinical Relevance of- Limit of Detection (LOD) - Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML)
- Author
-
Palmieri, Raffaele, primary, Piciocchi, Alfonso, additional, Arena, Valentina, additional, Maurillo, Luca, additional, Del Principe, Maria Ilaria, additional, Paterno, Giovangiacinto, additional, Ottone, Tiziana, additional, Divona, Mariadomenica, additional, Lavorgna, Serena, additional, Irno Consalvo, Maria, additional, Conti, Consuelo, additional, Attrotto, Cristina, additional, Fraboni, Daniela, additional, Voso, Maria Teresa, additional, Arcese, William, additional, Venditti, Adriano, additional, and Buccisano, Francesco, additional
- Published
- 2020
- Full Text
- View/download PDF
34. Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia
- Author
-
Palmieri, Raffaele, primary, Buccisano, Francesco, additional, Maurillo, Luca, additional, Del Principe, Maria I., additional, Paterno, Giovangiacinto, additional, Venditti, Adriano, additional, Martinelli, Giovanni, additional, and Cerchione, Claudio, additional
- Published
- 2020
- Full Text
- View/download PDF
35. Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness
- Author
-
Palmieri, Raffaele, primary, Paterno, Giovangiacinto, additional, De Bellis, Eleonora, additional, Mercante, Lisa, additional, Buzzatti, Elisa, additional, Esposito, Fabiana, additional, Del Principe, Maria Ilaria, additional, Maurillo, Luca, additional, Buccisano, Francesco, additional, and Venditti, Adriano, additional
- Published
- 2020
- Full Text
- View/download PDF
36. Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the Campus ALL Network
- Author
-
Del Principe, Maria Ilaria, primary, Buzzatti, Elisa, additional, Piciocchi, Alfonso, additional, Forghieri, Fabio, additional, Bonifacio, Massimiliano, additional, Lessi, Federica, additional, Imbergamo, Silvia, additional, Orciuolo, Enrico, additional, Rossi, Giovanni, additional, Fracchiolla, Nicola, additional, Trappolini, Silvia, additional, Neri, Benedetta, additional, Sarlo, Chiara, additional, Zappasodi, Patrizia, additional, Dargenio, Michelina, additional, Cefalo, Mariagiovanna, additional, Irno-Consalvo, Maria Antonietta, additional, Conti, Consuelo, additional, Paterno, Giovangiacinto, additional, De Angelis, Gottardo, additional, Sciumè, Mariarita, additional, Della Starza, Irene, additional, Venditti, Adriano, additional, Foà, Robin, additional, and Guarini, Anna Rita, additional
- Published
- 2019
- Full Text
- View/download PDF
37. Pneumocystis jirovecii pneumonia in patients with previously untreated acute myeloid leukaemia.
- Author
-
Paterno, Giovangiacinto, Guarnera, Luca, Palmieri, Raffaele, Del Prete, Valentina, Bonanni, Fabrizio, Buzzatti, Elisa, Moretti, Federico, Casciani, Paola, Savi, Arianna, Di Cave, David, Maurillo, Luca, Buccisano, Francesco, Venditti, Adriano, and Del Principe, Maria Ilaria
- Subjects
- *
ACUTE myeloid leukemia , *OLDER patients , *SMOKING , *IMMUNOCOMPROMISED patients , *HIV infections , *CANCER chemotherapy , *PNEUMOCYSTIS pneumonia - Abstract
Background: Several studies in immunocompromised patients, such as those with HIV infection, undergoing cancer chemotherapy or organ transplant, have led to the development of guidelines on the use of prophylaxis to prevent Pneumocystis jirovecii pneumonia (PJP), in these specific conditions. Instead, since the association between PJP and acute myeloid leukaemia (AML) is not clearly defined, the role of prophylaxis in patients with AML is not yet established. Methods: We retrospectively analysed 251 consecutive patients with newly diagnosed non‐M3‐AML, admitted at the Hematology Unit of University Tor Vergata in Rome, during the period 2010–2020. The aim of the study was to evaluate the incidence of PJP among AML patients during their first hospital admission, and to identify subjects at a high risk to develop PJP. Results: Among 251 consecutive patients with non‐M3‐AML, 67 bronchoalveolar lavages (BAL) were performed. PJP was proven in 11/67 (16.7%) subjects undergoing BAL (11 males, median age 71 years), with an incidence of 4.3%. The most common reason for BAL execution were radiological findings such as ground‐glass opacities (6/11, 55%) and atypical patterns like consolidations and nodules (5/11, 45%). One patient died because of PJP after 11 days of trimethoprim/sulfamethoxazole therapy. In multivariate analysis older age and smoking habit were independent factors significantly associated with PJP (p =.021 and 0.017 respectively). Conclusion: We conclude that PJP infection is not uncommon among patients with AML. If intensive chemotherapy is planned, physicians should be aware of this risk and prophylaxis should be considered, particularly in older patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
38. Diagnostic Performance and Safety of Bronchoalveolar Lavage in Thrombocytopenic Haematological Patients for Invasive Fungal Infections Diagnosis: A Monocentric, Retrospective Experience
- Author
-
Cefalo, Mariagiovanna, Puxeddu, Ermanno, Sarmati, Loredana, Paterno, Giovangiacinto, Fontana, Carla, Nasso, Daniela, Pane, Gloria, De Bellis, Eleonora, Palmieri, Raffaele, Buzzati, Elisa, Meconi, Federico, Laureana, Roberta, Casciani, Paola, Zizzari, Anna Giulia, Rogliani, Paola, de Fabritiis, Paolo, Maurillo, Luca, Buccisano, Francesco, Cantonetti, Maria, Arcese, William, Venditti, Adriano, and Del Principe, Maria Ilaria
- Subjects
Bronchoalveolar lavage ,Pulmonary aspergillosis ,Galactomannan antigen ,Original Article ,Hematologic malignancies ,respiratory system ,Thrombocytopenia ,respiratory tract diseases - Abstract
Background Although bronchoalveolar lavage (BAL) measurements of galactomannan antigen (GM) seems to be more sensitive than serum testing to detect invasive fungal infection (IFI), a consensus on the most appropriate diagnostic threshold of the BAL GM test is still unclear. Moreover, there is uncertainty as to whether BAL is a safe procedure in patients with hematological malignancies (HM) and thrombocytopenia. Objectives Based on this background, 102 adult patients with HM and associated thrombocytopenia were retrospectively analyzed with the dual aim of 1) determining whether BAL is a safe and feasible procedure; and, 2) identifying the most appropriate threshold for GM positivity in the diagnosis of IFI. Patients/Methods each BAL was considered as one case/patient. One hundred twelve BALs were carried out in 102 HM patients: at the time of the BAL, the median platelet count (PLTs) in all patients was 47×109/L (1–476), and 31 patients (27%) had PLTs< 20×109/L. Results complications from the BAL were infrequent (3.5%) and mild. No bleeding was reported. The BAL GM cut off of >0.8 was associated with the best diagnostic accuracy (sensitivity 72.97% and specificity 80%). Antifungal treatment of patients with BAL GM >0.8 resulted in a clinical-radiological improvement in 35/41 patients (85%). Conclusions BAL was a safe procedure also in thrombocytopenic patients, permitting an IFI diagnosis not otherwise identifiable using EORTC/MSG criteria. Our data suggest that a BAL GM value of>0.8 represents the most useful cut-off in terms of sensibility and specificity. Further prospective studies on a more significant number of patients are needed to confirm these results.
- Published
- 2019
39. Multiparametric Flow-Cytometry Is a Reliable Tool for Measurable Residual Disease Assessment and Risk-Stratification of FLT3-Mutated AML Patients
- Author
-
Palmieri, Raffaele, primary, Maurillo, Luca, additional, Piciocchi, Alfonso, additional, Del Principe, Maria Ilaria, additional, Arena, Valentina, additional, Soddu, Stefano, additional, Di Veroli, Ambra, additional, Paterno, Giovangiacinto, additional, De Bellis, Eleonora, additional, Cerretti, Raffaella, additional, De Angelis, Gottardo, additional, Mariotti, Benedetta, additional, Ottone, Tiziana, additional, Divona, Mariadomenica, additional, Lavorgna, Serena, additional, Irno Consalvo, Maria, additional, Conti, Consuelo, additional, Attrotto, Cristina, additional, Fraboni, Daniela, additional, Arcese, William, additional, Voso, Maria Teresa, additional, Venditti, Adriano, additional, and Buccisano, Francesco, additional
- Published
- 2019
- Full Text
- View/download PDF
40. Mutational Profile of Leukemic Stem Cells in FLT3-ITD Mutated AML
- Author
-
Ottone, Tiziana, primary, Travaglini, Serena, additional, Alfonso, Valentina, additional, Angelini, Daniela, additional, Guerrera, Gisella, additional, Lavorgna, Serena, additional, Divona, Mariadomenica, additional, Nardozza, Anna Maria, additional, Cristiano, Antonio, additional, irno Consalvo, Maria, additional, de Bardi, Marco, additional, Neri, Benedetta, additional, Marchesi, Francesco, additional, Gurnari, Carmelo, additional, Paterno, Giovangiacinto, additional, Martini, Vincenza, additional, Battistini, Luca, additional, Venditti, Adriano, additional, Buccisano, Francesco, additional, Arcese, William, additional, Lo-Coco, Francesco, additional, and Voso, Maria Teresa, additional
- Published
- 2019
- Full Text
- View/download PDF
41. Validation of SIE, Sies, GITMO Operational Criteria for the Definition of Fitness in Elderly Patients Affected with Acute Myeloid Leukemia: A Six-Years Retrospective Real-Life Experience
- Author
-
Palmieri, Raffaele, primary, Paterno, Giovangiacinto, additional, De Bellis, Eleonora, additional, Buzzatti, Elisa, additional, Rossi, Valentina, additional, Di Veroli, Ambra, additional, Esposito, Fabiana, additional, Mercante, Lisa, additional, Gurnari, Carmelo, additional, Casciani, Paola, additional, Del Principe, Maria Ilaria, additional, Maurillo, Luca, additional, Voso, Maria Teresa, additional, Arcese, William, additional, Venditti, Adriano, additional, and Buccisano, Francesco, additional
- Published
- 2019
- Full Text
- View/download PDF
42. Leukemic Stem Cells Persistence Measured By Multiparametric Flow Cytometry Is a Biomarker of Poor Prognosis in Adult Patients with Acute Myeloid Leukemia
- Author
-
Buccisano, Francesco, primary, Palmieri, Raffaele, additional, Irno Consalvo, Maria, additional, Piciocchi, Alfonso, additional, Maurillo, Luca, additional, Del Principe, Maria Ilaria, additional, Arena, Valentina, additional, Soddu, Stefano, additional, Di Veroli, Ambra, additional, Paterno, Giovangiacinto, additional, De Bellis, Eleonora, additional, Fraboni, Daniela, additional, Conti, Consuelo, additional, Voso, Maria Teresa, additional, Arcese, William, additional, and Venditti, Adriano, additional
- Published
- 2019
- Full Text
- View/download PDF
43. DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE.
- Author
-
Cefalo, Mariagiovanna, primary, Puxeddu, Ermanno, additional, Sarmati, Loredana, additional, Paterno, Giovangiacinto, additional, Fontana, Carla, additional, Nassa, Daniela, additional, Pane, Gloria, additional, De Bellis, Eleonora, additional, Palmieri, Raffaele, additional, Buzzatti, Elisa, additional, Meconi, Federico, additional, Laureana, Roberta, additional, Casciani, Paola, additional, Zizzari, Anna Giulia, additional, Rogliani, Paola, additional, De Fabritiis, Paolo, additional, Maurillo, Luca, additional, Buccisano, Francesco, additional, Cantonetti, Maria, additional, Arcese, William, additional, Venditti, Adriano, additional, and Del Principe, Maria Ilaria, additional
- Published
- 2019
- Full Text
- View/download PDF
44. An evaluation of enasidenib for the treatment of acute myeloid leukemia
- Author
-
Del Principe, Maria Ilaria, primary, Paterno, Giovangiacinto, additional, Palmieri, Raffaele, additional, Maurillo, Luca, additional, Buccisano, Francesco, additional, and Venditti, Adriano, additional
- Published
- 2019
- Full Text
- View/download PDF
45. Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome
- Author
-
Del Principe, Maria Ilaria, primary, Buccisano, Francesco, additional, Soddu, Stefano, additional, Maurillo, Luca, additional, Cefalo, Mariagiovanna, additional, Piciocchi, Alfonso, additional, Consalvo, Maria Irno, additional, Paterno, Giovangiacinto, additional, Sarlo, Chiara, additional, De Bellis, Eleonora, additional, Zizzari, Annagiulia, additional, De Angelis, Gottardo, additional, Fraboni, Daniela, additional, Divona, Mariadomenica, additional, Voso, Maria Teresa, additional, Sconocchia, Giuseppe, additional, Del Poeta, Giovanni, additional, Lo-Coco, Francesco, additional, Arcese, William, additional, Amadori, Sergio, additional, and Venditti, Adriano, additional
- Published
- 2018
- Full Text
- View/download PDF
46. Pattern of Central Nervous System (CNS) Involvement in Adult Acute Myeloid Leukemia (AML) and Its Impact on Outcome
- Author
-
Del Principe, Maria Ilaria, primary, Buccisano, Francesco, additional, Soddu, Stefano, additional, Maurillo, Luca, additional, Cefalo, Mariagiovanna, additional, Piciocchi, Alfonso, additional, Paterno, Giovangiacinto, additional, Sarlo, Chiara, additional, De Angelis, Gottardo, additional, Forte, Vittorio, additional, Irno Consalvo, Maria, additional, Fraboni, Daniela, additional, De Bellis, Eleonora, additional, Zizzari, Annagiulia, additional, Divona, Mariadomenica, additional, Sconocchia, Giuseppe, additional, Voso, Maria Teresa, additional, Del Poeta, Giovanni, additional, Lo Coco, Francesco, additional, Amadori, Sergio, additional, Arcese, William, additional, and Venditti, Adriano, additional
- Published
- 2016
- Full Text
- View/download PDF
47. Intravenous Administration of Rituximab in the Treatment of Primary Cutaneous B-Cell Lymphomas (PCBCLs): A Retrospective Study
- Author
-
Paterno, Giovangiacinto, primary, Zizzari, Annagiulia, additional, Nasso, Daniela, additional, Tonialini, Lorenzo, additional, Angeloni, Cecilia, additional, Vaccarini, Sara, additional, Postorino, Massimiliano, additional, Pupo, Livio, additional, Franceschini, Luca, additional, Provenzano, Ida, additional, Rizzo, Manuela, additional, Giannì, Laura, additional, Anemona, Lucia, additional, Mauriello, Alessandro, additional, Lombardo, Giuseppe Alfonso, additional, Scala, Enrico, additional, and Cantonetti, Maria, additional
- Published
- 2014
- Full Text
- View/download PDF
48. Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells.
- Author
-
Travaglini, Serena, Angelini, Daniela Francesca, Alfonso, Valentina, Guerrera, Gisella, Lavorgna, Serena, Divona, Mariadomenica, Nardozza, Anna Maria, Consalvo, Maria Irno, Fabiani, Emiliano, De Bardi, Marco, Neri, Benedetta, Forghieri, Fabio, Marchesi, Francesco, Paterno, Giovangiacinto, Cerretti, Raffaella, Barragan, Eva, Fiori, Valentina, Dominici, Sabrina, Del Principe, Maria Ilaria, and Venditti, Adriano
- Subjects
ACUTE myeloid leukemia ,GENETIC mutation ,PROTEIN-tyrosine kinases ,PROGENITOR cells ,FLUORESCENCE - Abstract
Acute myeloid leukemia (AML) with FLT3-ITD mutations (FLT3-ITD
mut ) remains a therapeutic challenge, with a still high relapse rate, despite targeted treatment with tyrosine kinase inhibitors. In this disease, the CD34/CD123/CD25/CD99+ leukemic precursor cells (LPCs) phenotype predicts for FLT3-ITD-positivity. The aim of this study was to characterize the distribution of FLT3-ITD mutation in different progenitor cell subsets to shed light on the subclonal architecture of FLT3-ITDmut AML. Using high-speed cell sorting, we sequentially purified LPCs and CD34+ progenitors in samples from patients with FLT3-ITDmut AML (n = 12). A higher FLT3-ITDmut load was observed within CD34/CD123/CD25/CD99+ LPCs, as compared to CD34+ progenitors (CD123+/−,CD25−,CD99low/−) (p = 0.0005) and mononuclear cells (MNCs) (p < 0.0001). This was associated with significantly increased CD99 mean fluorescence intensity in LPCs. Significantly higher FLT3-ITDmut burden was also observed in LPCs of AML patients with a small FLT3-ITDmut clones at diagnosis. On the contrary, the mutation burden of other myeloid genes was similar in MNCs, highly purified LPCs and/or CD34+ progenitors. Treatment with an anti-CD99 mAb was cytotoxic on LPCs in two patients, whereas there was no effect on CD34+ cells from healthy donors. Our study shows that FLT3-ITD mutations occur early in LPCs, which represent the leukemic reservoir. CD99 may represent a new therapeutic target in FLT3-ITDmut AML. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
49. ELN2017 risk stratification improves outcome prediction when applied to the prospective, GIMEMA AML1310 protocol. ELN 2017 risk to guide treatment strategy in AML
- Author
-
Buccisano, Francesco, Palmieri, Raffaele, Piciocchi, Alfonso, Arena, Valentina, Candoni, Anna, Melillo, Lorella, Calafiore, Valeria, Cairoli, Roberto, Fabritiis, Paolo de, Storti, Gabriella, Salutari, Prassede, Lanza, Francesco, Martinelli, Giovanni, Luppi, Mario, Capria, Saveria, Maurillo, Luca, Del Principe, Maria Ilaria, Paterno, Giovangiacinto, Irno-Consalvo, Maria Antonietta, Ottone, Tiziana, Lavorgna, Serena, Voso, Maria Teresa, Fazi, Paola, Vignetti, Marco, Arcese, William, and Venditti, Adriano
- Abstract
The 2017 version of the ELN recommendations, by integratingcytogenetics and mutational status of specific genes,sort out patients with Acute Myeloid Leukemia into 3 prognostically distinct risk categories: favorable(ELN2017-FR), intermediate(ELN2017-IR) and adverse(ELN2017-AR). We performed a post-hoc analysis of the GIMEMA AML1310 trial to investigate the applicability of the ELN2017 risk stratification to our study population.
- Published
- 2021
- Full Text
- View/download PDF
50. ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
- Author
-
Luca Maurillo, Adriano Venditti, Maria Teresa Voso, Paolo de Fabritiis, Giovanni Martinelli, Marco Vignetti, Gabriella Storti, Mario Luppi, Francesco Buccisano, Francesco Lanza, Valentina Arena, Giovangiacinto Paterno, Lorella Melillo, Prassede Salutari, Roberto Cairoli, Serena Lavorgna, Paola Fazi, Anna Candoni, Tiziana Ottone, Alfonso Piciocchi, Maria Antonietta Irno Consalvo, Saveria Capria, Raffaele Palmieri, Maria Ilaria Del Principe, William Arcese, Valeria Calafiore, Buccisano, F, Palmieri, R, Piciocchi, A, Arena, V, Candoni, A, Melillo, L, Calafiore, V, Cairoli, R, de Fabritiis, P, Storti, G, Salutari, P, Lanza, F, Martinelli, G, Luppi, M, Capria, S, Maurillo, L, Del Principe, M, Paterno, G, Consalvo, M, Ottone, T, Lavorgna, S, Voso, M, Fazi, P, Vignetti, M, Arcese, W, Venditti, A, Buccisano, Francesco, Palmieri, Raffaele, Piciocchi, Alfonso, Arena, Valentina, Candoni, Anna, Melillo, Lorella, Calafiore, Valeria, Cairoli, Roberto, de Fabritiis, Paolo, Storti, Gabriella, Salutari, Prassede, Lanza, Francesco, Martinelli, Giovanni, Luppi, Mario, Capria, Saveria, Maurillo, Luca, Del Principe, Maria Ilaria, Paterno, Giovangiacinto, Irno Consalvo, Maria Antonietta, Ottone, Tiziana, Lavorgna, Serena, Voso, Maria Teresa, Fazi, Paola, Vignetti, Marco, Arcese, William, and Venditti, Adriano
- Subjects
medicine.medical_specialty ,Humans ,Neoplasm, Residual ,Prognosis ,Prospective Studies ,Risk Assessment ,Transplantation, Homologous ,autologous stem cell transplantation ,post hoc analysi ,overall survival ,Article ,remission ,male ,allogeneic stem cell transplantation ,MED/15 - MALATTIE DEL SANGUE ,Internal medicine ,medicine ,Overall survival ,Mutational status ,human ,outcome assessment ,business.industry ,cytogenetic ,adult ,flow cytometry ,Complete remission ,Myeloid leukemia ,Hematology ,prediction ,Settore MED/15 ,major clinical study ,female ,Acute myeloid leukemia, gimema aml1310, outcome prediction, risk stratification ,Risk stratification ,survival analysi ,minimal residual disease ,treatment outcome ,Population study ,Risk categorization ,business ,Outcome prediction ,intermediate risk patient ,prospective study - Abstract
The 2017 version of the European LeukemiaNet (ELN) recommendations, by integrating cytogenetics and mutational status of specific genes, divides patients with acute myeloid leukemia into 3 prognostically distinct risk categories: favorable (ELN2017-FR), intermediate (ELN2017-IR), and adverse (ELN2017-AR). We performed a post hoc analysis of the GIMEMA (Gruppo Italiano Malattie EMatologiche dell’Adulto) AML1310 trial to investigate the applicability of the ELN2017 risk stratification to our study population. In this trial, after induction and consolidation, patients in complete remission were to receive an autologous stem cell transplant (auto-SCT) if categorized as favorable risk or an allogeneic stem cell transplant (allo-SCT) if adverse risk. Intermediate-risk patients were to receive auto-SCT or allo-SCT based on the postconsolidation levels of measurable residual disease as measured by using flow cytometry. Risk categorization was originally conducted according to the 2009 National Comprehensive Cancer Network recommendations. Among 500 patients, 445 (89%) were reclassified according to the ELN2017 criteria: ELN2017-FR, 186 (41.8%) of 455; ELN2017-IR, 179 (40.2%) of 445; and ELN2017-AR, 80 (18%) of 455. In 55 patients (11%), ELN2017 was not applicable. Two-year overall survival (OS) was 68.8%, 51.3%, 45.8%, and 42.8% for the ELN2017-FR, ELN2017-IR, ELN2017-not classifiable, and ELN2017-AR groups, respectively (P < .001). When comparing the 2 different transplant strategies in each ELN2017 risk category, a significant benefit of auto-SCT over allo-SCT was observed among ELN2017-FR patients (2-year OS of 83.3% vs 66.7%; P = .0421). The 2 transplant procedures performed almost equally in the ELN2017-IR group (2-year OS of 73.9% vs 70.8%; P = .5552). This post hoc analysis of the GIMEMA AML1310 trial confirms that the ELN2017 classification is able to accurately discriminate patients with different outcomes and who may benefit from different transplant strategies. This trial was registered as EudraCT number 2010-023809-36 and at www.clinicaltrials.gov as #NCT01452646.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.